A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
19h agoen
From the article
Conditions : Hepatocellular Carcinoma Interventions : Drug: SHR-8068+ Adebrelimab+ Bevacizumab; Drug: SHR-8068 Placebo+ Adebrelimab Placebo+ Bevacizumab Placebo; Drug: SHR-8068 Placebo +Adebrelimab+ Bevacizumab Sponsors : Suzhou Suncadia Biopharmaceuticals Co., Ltd. Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
ClinicalKey
clinicalkey.com·1mo ago
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study
doi.org·19d ago
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
doi.org·6d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.